3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
88
Neoplasms
11
Neoplasm Metastasis
10
Glioma
8
Ovarian Neoplasms
6
Melanoma
6
Glioblastoma
6
Squamous Cell Carcinoma of Head and Neck
5
Liposarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma
4
Recurrence
4
Medulloblastoma
4
Endometrial Neoplasms
4
Diffuse Intrinsic Pontine Glioma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Neuroblastoma
3
Neoplasms by Site
3
Lymphoma
3
Hereditary Sensory and Autonomic Neuropathies
3
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Breast Diseases
3
Astrocytoma
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Endocrine Neoplasia Type 1
2
Interventions
Pemetrexed
39
Cisplatin
33
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Imatinib Mesylate
3
Cerebral Decortication
3
tislelizumab
2
sargramostim
2
fludarabine phosphate
2
defactinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Mesothelioma
×
ribociclib
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts